文献速递临床试验与 GCP

人血白蛋白对动脉瘤性蛛网膜下腔出血临床结局的有效性:随机对照(HASH)试验方案

Effectiveness of human albumin for clinical outcome in aneurysmal subarachnoid hemorrhages: a protocol for randomized controlled (HASH) trial.
PubMed 文献 · Trials · 2025-02-14

本研究为单中心、开放标签、前瞻性、平行组随机对照试验,计划于2024年8月至2027年7月在卡塔尔多哈哈马德综合医院开展,样本量84例(每组42例),比较人血白蛋白增强液体管理与仅用晶体液的标准液体治疗对动脉瘤性蛛网膜下腔出血患者改良Rankin量表良好评分的影响。主要结局为二分法改良Rankin量表(良好0-2分,不良3-6分),次要结局包括症状性血管痉挛、经颅多普勒流速和脉搏指示连续心排血量(PiCCO)参数。

要点

  • 首个比较人血白蛋白增强液体管理与晶体液标准治疗用于动脉瘤性蛛网膜下腔出血的随机对照试验。
  • 计划纳入84例(每组42例),主要结局为改良Rankin量表良好评分(0-2分)与不良评分(3-6分)的二分法比较。
  • 次要结局包括症状性血管痉挛、经颅多普勒流速及PiCCO参数。

核心结论

  • 该试验旨在提供人血白蛋白用于实现最佳液体管理方案以改善动脉瘤性蛛网膜下腔出血患者临床结局的一手证据。

研究设计与样本

  • 单中心、开放标签、前瞻性、平行组随机对照试验,计划于2024年8月至2027年7月在卡塔尔多哈哈马德综合医院开展,样本量84例(每组42例)。

关键数值与推荐

  • 主要结局为二分法改良Rankin量表:良好评分(0-2分)与不良评分(3-6分)。
  • 次要结局包括症状性血管痉挛、经颅多普勒流速和PiCCO参数。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aneurysmal subarachnoid hemorrhage (aSAH) is a dreadful acute neurological condition with an overwhelmingly high rate of associated morbidities and mortality. Despite leaping advancement in neurosurgical techniques and imaging modalities, there is no substantiative improvement in the overall prognosis for aSAH. Cerebral vasospasm remains the predominant cause of associated morbidities. Human albumin has been used in different neurological conditions, including head trauma, intracerebral hemorrhages, and ischemic strokes, with favorable outcomes. However, its beneficial use in aSAH has not been sufficiently explored until recently a published systematic review by our team. In view of the scarcity of published data and lack of robust evidence, our group has designed the first-ever RCT to compare the use of human albumin-enhanced fluid management versus standard fluid therapy with crystalloids in patients with aSAH. METHODS: This single-center open-label, prospective, parallel group randomized control trial will be conducted at Hamad General Hospital, Doha, Qatar, from August 2024 to July 2027. A sample size of 84 (42 in each arm) has been calculated to be sufficient to detect a clinically significant difference in the modified Rankin scale good score between two groups (human-albumin induced volume expansion therapy versus crystalloid only) for fluid management in aneurysmal subarachnoid hemorrhage patients. The primary outcome will be based on a dichotomized modified Rankin scale [good grades (0-2) and poor grades (3-6)], while the secondary outcome will include symptomatic vasospasm, transcranial Doppler velocities, and Pulse index Contour Cardiac Output (PiCCO) parameters. DISCUSSION: The trial aims to provide firsthand evidence on the beneficial use of human albumin to achieve an optimal fluid management regime to explore its potential role in improving clinical outcomes in patients with aSAH. TRIAL REGISTRATION: ClinicalTrials.gov NCT06548477. Registered on August 9, 2024. https://clinicaltrials.gov/search?term=NCT06548477 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Ali A, Khan M, Shaikh N, et al. Effectiveness of human albumin for clinical outcome in aneurysmal subarachnoid hemorrhages: a protocol for randomized controlled (HASH) trial. Trials. 2025. PMID: 39953562. doi:10.1186/s13063-025-08762-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。